Sarcomas and Histiocytosis
Research Program
Leaders
Where we are
SJD Barcelona Children's Hospital
Related websites
SJD Barcelona Children’s Hospital Our group aims to generate a knowledge base on developmental sarcomas and Langerhans cell histiocytosis (LCH) with a view to improving diagnosis, prognosis and treatment.
Since 2014 we have been a consolidated AGAUR research group (Government of Catalonia, references 2014 SGR 1398 and 2017 SGR 1672).
Research lines
Our specific activities are:
- The study of the aetiology of sarcomas and LCH and the phenotypic and genotypic characterisation of the different clinical subtypes.
- The investigation of the existence of cancer stem cells or progenitor cells.
- Improving treatments for patients with sarcomas by studying preclinical pharmacology.
- The development of IGF-1R-targeted therapies for sarcoma.
- The study of molecular pathways and therapies aimed at histiocytosis.
- Pathobiology of Vascular Tumours and Malformations
- Sarcomas Epigenetic
Scientific objectives
- To develop innovative pharmacological treatments for extracranial paediatric solid tumours such as Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma and LCH.
- To describe the cell of origin in Ewing's sarcoma and to develop experimental models to reproduce the tumourigenesis process.
Area/Field of expertise
Development of cell models and patient-derived xenografts (PDX) of paediatric solid tumours (rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, Wilms tumour, germ cell tumours) from biobank samples.
Efficacy tests of anticancer agents used to treat paediatric solid tumours.
Epigenomics and chromatin conformation studies using chip-Seq, CHIP-CHIP, HI-Seq.
Group members
-
Jefe de Grupo Senior
-
Maria Inmaculada Hernandez Muñoz
Investigador colaborador
-
Investigador
-
Investigador pre-doc
-
Investigador
-
Ayudante de investigación
-
Ayudante de investigación
-
Investigador
-
Ayudante de investigación
-
Investigador pre-doc
-
Investigador
-
Investigador post-doc
-
Investigador post-doc
-
Ayudante de investigación
-
Investigador
-
Investigador
-
Investigador post-doc
-
Ayudante de investigación
-
Ayudante de investigación
-
Investigador
-
Investigador pre-doc
-
Investigador pre-doc
-
Investigador pre-doc
-
Investigador post-doc
-
Técnico
-
Ayudante de investigación
-
Investigador pre-doc
-
Ayudante de investigación
-
Ayudante de investigación
-
Oriol Martín Solé
Ayudante de investigación
-
Investigador post-doc
Last Publications
- Balaguer-Lluna L, Gene-Olaciregui N, Aschero MR, Resa-Parés C, Paco-Mercader S, Cuadrado-Vilanova M, Burgeño-Sandoval V, Baulenas-Farrés M, Monterrubio C, Manzanares-Quintela A, Rodriguez E, Lavarino C, Mora J and Carcaboso AM Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas. JOURNAL OF NEURO-ONCOLOGY . 172(3): 599-611.
- Chicón-Bosch, M, Sánchez-Serra, S, Rosàs-Lapeña, M, Costa-Fraga, N, Besalú-Velázquez, J, Illa-Bernadí, J, Mateo-Lozano S, Cidre-Aranaz, F, Grünewald, TGP, Díaz-Lagares, A, Lopez-Alemany, R and Tirado, OM Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis. MOLECULAR ONCOLOGY . 19(4): 1002-1028.
- Mora J, Chan GCF, Morgenstern DA, Amoroso L, Nysom K, Faber J, Wingerter A, Bear MK, Rubio-San-Simon A, de Las Heras BM, Tornøe K, Düring M and Kushner BH The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial NATURE COMMUNICATIONS . 16(1): 1636-1636.
Projects
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Ayuda Ramon y Cajal. Beneficiari: Sandra Castillo
- Leader
- Sandra Castillo Diez
- Funding entities:
- Ministerio De Ciencia E Innovacion
- Code
- RYC2022-035574-I
- Starting - finishing date:
- 2024 - 2029
- Project name:
- Subvenció per a la incorporació de personal de suport als grups de recerca, corresponent als anys 2023-2025
- Leader
- Jaume Mora Graupera
- Funding entities:
- Generalitat de Catalunya
- Code
- SLT028/23/000308
- Starting - finishing date:
- 2023 - 2026
Theses
-
The role of PRC1.1 in rhabdomyosarcoma tumorigenesis
- Author
- Táboas Outón, Pablo
- Institution
- UNIVERSIDAD DE BARCELONA
-
Unveiling the role of the Mediator complex in Ewing sarcoma tumorigenesis
- Author
- Cuervas Oliveras, Irene
- Institution
- UNIVERSIDAD DE BARCELONA
-
Target Therapy in Rhabdomyosarcoma: Discovering new targets and apportunities
- Author
- Prada Varela, Estela
- Institution
- UNIVERSIDAD DE BARCELONA
News
-
A study tests the effectiveness of anticancer drugs in the treatment of PTEN hamartoma tumor syndrome
This discovery could facilitate earlier diagnosis in children and also help slow the effects of the syndrome from its earliest stages, significantly improving patients' quality of life.
-
New discoveries about the EWS-FLI oncogene involved in the development of Ewing's tumor
Researchers from IRSJD · SJD Barcelona Children’s Hospital and IRB Barcelona have successfully developed Drosophila models expressing the EWS-FLI oncogene at varying levels, overcoming previous toxicity challenges and enabling detailed study of Ewing sarcoma's oncogenic pathways.
-
The Catalan Tumour Bank Network launches a new corporate identity and website
The Xarxa de Bancs de Tumor de Catalunya (XBTC) has renewed its corporate identity and website to project a more dynamic and local network in the biomedicine and health ecosystem.
More activities
-
Defensa tesi doctoral: Pablo Táboas Outón
Auditori Plaza · Hospital Sant Joan de Déu and online
-
Defensa tesi doctoral: Irene Cuervas Oliveras
Auditori Plaza · Hospital Sant Joan de Déu
-
Defensa tesi doctoral: María Sánchez Jiménez
Auditori Plaza · Hospital Sant Joan de Déu and online